Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.

Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

Antibiotics (Basel). 2020 Mar 29;9(4). pii: E145. doi: 10.3390/antibiotics9040145.

2.

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.

Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H.

World J Gastrointest Oncol. 2019 Oct 15;11(10):887-897. doi: 10.4251/wjgo.v11.i10.887.

3.

Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.

Tsuji Y, Kawaratani H, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Takaya H, Shimozato N, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H.

Dig Dis. 2019 Oct 25:1-6. doi: 10.1159/000504044. [Epub ahead of print]

PMID:
31655803
4.

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.

Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H.

BMC Gastroenterol. 2019 Oct 21;19(1):167. doi: 10.1186/s12876-019-1082-1.

5.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.

Cells. 2019 Sep 26;8(10). pii: E1153. doi: 10.3390/cells8101153.

6.

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.

Nakanishi K, Namisaki T, Mashitani T, Kaji K, Ozaki K, Saikawa S, Sato S, Inoue T, Sawada Y, Kitagawa K, Takaya H, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.

Nutrients. 2019 Sep 7;11(9). pii: E2140. doi: 10.3390/nu11092140.

7.

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.

Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Dec;25(4):381-389. doi: 10.3350/cmh.2019.0037. Epub 2019 Aug 13.

8.

Effect of furosemide on muscle cramps in patients with liver cirrhosis.

Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

J Gastroenterol Hepatol. 2020 Jan;35(1):76-81. doi: 10.1111/jgh.14820. Epub 2019 Aug 16.

PMID:
31385352
9.

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.

Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15.

PMID:
31177586
10.

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.

Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H.

World J Gastrointest Oncol. 2019 May 15;11(5):424-435. doi: 10.4251/wjgo.v11.i5.424.

11.

Identification of clinical risk factors for histological progression of primary biliary cholangitis.

Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14.

PMID:
31021038
12.

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

Clin Mol Hepatol. 2019 Mar;25(1):65-73. doi: 10.3350/cmh.2018.0070. Epub 2019 Feb 25.

13.

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.

United European Gastroenterol J. 2018 Nov;6(9):1401-1409. doi: 10.1177/2050640618779660. Epub 2018 May 25.

14.

Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.

Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Mar;49(3):284-295. doi: 10.1111/hepr.13281. Epub 2018 Dec 12.

PMID:
30365236
15.

Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.

Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H.

Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19.

16.

Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.

Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Feb;49(2):232-238. doi: 10.1111/hepr.13249. Epub 2018 Oct 9.

PMID:
30198141
17.

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

J Gastrointest Oncol. 2018 Aug;9(4):741-749. doi: 10.21037/jgo.2018.05.13.

18.

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H.

Hepatol Commun. 2017 Sep 19;1(9):928-945. doi: 10.1002/hep4.1104. eCollection 2017 Nov.

19.

Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report.

Kaneko M, Mitoro A, Yoshida M, Sawai M, Okura Y, Furukawa M, Namisaki T, Moriya K, Akahane T, Kawaratani H, Kitade M, Kaji K, Takaya H, Sawada Y, Seki K, Sato S, Fujii T, Yamao J, Obayashi C, Yoshiji H.

BMC Gastroenterol. 2018 Jan 19;18(1):16. doi: 10.1186/s12876-018-0743-9.

20.

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.

Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

World J Gastroenterol. 2017 Dec 21;23(47):8355-8366. doi: 10.3748/wjg.v23.i47.8355.

Supplemental Content

Loading ...
Support Center